

**losartan 100mg/ hydrochlorothiazide 25mg tablets
(Cozaar-Comp 100/25) (No. 296/06)**
Merck, Sharp & Dohme Ltd

Product Update

7 July 2006

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises the NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Losartan 100mg/hydrochlorothiazide 25mg tablet (Cozaar-Comp 100/25⁰) is accepted for use within NHS Scotland for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on hydrochlorothiazide or losartan monotherapy.

No increased costs are associated with this product compared with losartan (Cozaar[®]) 100 mg alone. Compared with a previously available combination product it reduces the tablet burden when higher doses of losartan and hydrochlorothiazide are required. This fixed dose combination is one of many options for the treatment of hypertension, including other less expensive angiotensin receptor blocker/diuretic combinations.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

*This assessment is based on data submitted by the applicant company up to and including **18 May 2006**.*

**Vice Chairman
Scottish Medicines Consortium**